Biocon rises as its arm receives MHRA, UK approval for YESINTEK, Biosimilar Ustekinumab
Biocon is currently trading at Rs. 334.20, up by 3.55 points or 1.07% from its previous closing of Rs. 330.65 on the BSE.
The scrip opened at Rs. 333.20 and has touched a high and low of Rs. 335.25 and Rs. 331.70 respectively. So far 19975 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 404.60 on 21-Jan-2025 and a 52 week low of Rs. 270.00 on 04-Jun-2024.
Last one week high and low of the scrip stood at Rs. 345.00 and Rs. 329.10 respectively. The current market cap of the company is Rs. 40076.03 crore.
The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 21.38% and 17.97% respectively.
Biocon’s subsidiary -- Biocon Biologics has received the Medicines and Healthcare products Regulatory Agency (MHRA), UK approval for YESINTEK, a biosimilar of Ustekinumab. YESINTEK is indicated for the treatment of adults and children from the age of 6 years and older with moderate to severe plaque psoriasis, and adults with active psoriatic arthritis or moderately to severely active Crohn’s disease. Clinical data from the trial program demonstrated that our Ustekinumab biosimilar has comparable safety and efficacy to the originator product.
In Europe, the European Commission (EC) recently granted marketing authorisation for Ustekinumab, allowing its commercialization in all European Union (EU) member states and the European Economic Area (EEA).
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
.jpg)
